You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePhentermine
Accession NumberDB00191  (APRD00093)
TypeSmall Molecule
GroupsApproved, Illicit
Description

A central nervous system stimulant and sympathomimetic with actions and uses similar to those of dextroamphetamine. It has been used most frequently in the treatment of obesity. [PubChem]. Some common brand names for phentermine are Adipex-P® and Suprenza™. Phentermine is also available in combination medications such as Qsymia®.

Structure
Thumb
Synonyms
alpha,alpha-Dimethylphenethylamine
Fentermina
Phenterminum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fastin Cap 30mgcapsule30 mgoralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-311999-02-02Canada
Suprenzatablet, orally disintegrating15 mg/1oralAkrimax Pharmaceuticals, LLC2012-12-14Not applicableUs
Suprenzatablet, orally disintegrating37.5 mg/1oralAkrimax Pharmaceuticals, LLC2012-12-14Not applicableUs
Suprenzatablet, orally disintegrating30 mg/1oralAkrimax Pharmaceuticals, LLC2012-12-14Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adipex-Ptablet37.5 mg/1oralPd Rx Pharmaceuticals, Inc.2011-02-14Not applicableUs
Adipex-Pcapsule37.5 mg/1oralTeva Select Brands1990-09-30Not applicableUs
Adipex-Ptablet37.5 mg/1oralTeva Select Brands1990-09-30Not applicableUs
Adipex-Ptablet37.5 mg/1oralA S Medication Solutions Llc1990-09-30Not applicableUs
Adipex-Ptablet37.5 mg/1oralA S Medication Solutions Llc1990-09-30Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralQualitest Pharmaceuticals2002-01-04Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralRx Change Co.2014-11-21Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralTAGI Pharma, Inc.2013-04-16Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralElite Laboratories, Inc.2014-05-01Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralPreferred Pharmaceuticals, Inc.2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralApotheca, Inc.2010-01-15Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralTeva Pharmaceuticals USA Inc2011-10-03Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralApotheca, Inc.1999-11-08Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralPd Rx Pharmaceuticals, Inc.2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralA S Medication Solutions Llc2003-10-23Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralNorthwind Pharmaceuticals2014-06-01Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralA S Medication Solutions Llc2003-10-23Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralProficient Rx LP2013-08-12Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralDispensing Solutions, Inc.1998-06-01Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralLeading Pharma, Llc2015-02-25Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralBlenheim Pharmacal, Inc.2013-03-18Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralLannett Company, Inc.2007-12-01Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralRebel Distributors Corp1983-02-03Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralLake Erie Medical DBA Quality Care Products2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralUnit Dose Services2005-04-15Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralMutual Pharmaceutical Company, Inc.2003-10-23Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralbryant ranch prepack1997-04-28Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralPreferred Pharmaceuticals, Inc.2012-07-25Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralPd Rx Pharmaceuticals, Inc.2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralBlenheim Pharmacal, Inc.2010-05-17Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralLannett Company, Inc.2011-07-20Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralAidarex Pharmaceuticals LLC2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralTAGI Pharma, Inc.2013-04-16Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralbryant ranch prepack2010-07-19Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralPreferred Pharmaceuticals, Inc.2014-08-25Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralApotheca, Inc.1998-06-01Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralLannett Company, Inc.2007-12-01Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralRebel Distributors Corp1999-11-08Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralPd Rx Pharmaceuticals, Inc.2013-08-12Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralUnit Dose Services2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralMutual Pharmaceutical Company, Inc.2003-10-23Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralPd Rx Pharmaceuticals, Inc.2003-10-23Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralbryant ranch prepack2007-12-01Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralPreferred Pharmaceuticals, Inc.2014-01-15Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralPd Rx Pharmaceuticals, Inc.2013-04-16Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralBlenheim Pharmacal, Inc.2009-12-30Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralLannett Company, Inc.2012-01-20Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralAidarex Pharmaceuticals LLC2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralTAGI Pharma, Inc.2011-03-08Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralbryant ranch prepack2003-10-23Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralPreferred Pharmaceuticals, Inc.2014-12-22Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralKvk Tech, Inc.2012-08-15Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralLannett Company, Inc.2007-12-01Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralSTAT Rx USA LLC2003-10-23Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralPd Rx Pharmaceuticals, Inc.2005-04-15Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralUnit Dose Services2012-08-07Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralH.J. Harkins Company, Inc.2003-10-23Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralPhysicians Total Care, Inc.2011-07-29Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralbryant ranch prepack2002-01-04Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralLegacy Pharmaceutical Packaging2014-04-02Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralLife Line Home Care Services, Inc.2008-03-31Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralBlenheim Pharmacal, Inc.2010-03-04Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralAidarex Pharmaceuticals LLC2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralUnit Dose Services2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-08-07Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralbryant ranch prepack2002-01-04Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralPreferred Pharmaceuticals, Inc.2014-11-10Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralKvk Tech, Inc.2012-08-07Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralLannett Company, Inc.2005-04-15Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralSTAT Rx USA LLC2007-12-01Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralPd Rx Pharmaceuticals, Inc.2011-03-08Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralUnit Dose Services2003-10-23Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralH.J. Harkins Company, Inc.2007-12-01Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralPhysicians Total Care, Inc.1997-04-28Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralProficient Rx LP2005-04-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralKeltman Pharmaceuticals Inc.2007-07-31Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralLeading Pharma, Llc2015-02-25Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralBlenheim Pharmacal, Inc.2010-03-04Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralEon Labs, Inc.1981-06-12Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralAidarex Pharmaceuticals LLC2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralA S Medication Solutions Llc2007-12-01Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralUnit Dose Services1981-06-12Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralPd Rx Pharmaceuticals, Inc.1997-04-28Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralbryant ranch prepack2012-08-07Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralPreferred Pharmaceuticals, Inc.2011-09-22Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralKvk Tech, Inc.2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralLannett Company, Inc.2010-07-19Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralAurolife Pharma, LLC2011-06-10Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralPd Rx Pharmaceuticals, Inc.2007-12-01Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralUnit Dose Services2003-10-23Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralMirror Pharmaceuticals LLC2011-11-01Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralPhysicians Total Care, Inc.1995-02-01Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralProficient Rx LP2012-08-07Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralLeading Pharma, Llc2015-03-09Not applicableUs
Phentermine Hydrochloridetablet30 mg/1oralBlenheim Pharmacal, Inc.2013-10-21Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralEon Labs, Inc.1981-06-12Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralCamber Pharmaceuticals, Inc.2014-04-02Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralUnit Dose Services2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralPd Rx Pharmaceuticals, Inc.2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralbryant ranch prepack2012-08-15Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralPreferred Pharmaceuticals Inc.2015-11-20Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralKvk Tech, Inc.2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralBlenheim Pharmacal, Inc.2013-03-11Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralEpic Pharma, LLC2015-04-15Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralNorthwind Pharmaceuticals2014-05-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralA S Medication Solutions Llc2012-08-15Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralMikah Pharma, Llc2014-05-01Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralRising Pharmaceuticals, Inc.2012-09-21Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralPreferred Pharmaceuticals, Inc.2012-03-05Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralApotheca, Inc.1999-11-08Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralTeva Pharmaceuticals USA Inc2011-03-09Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralApotheca, Inc.2002-08-12Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralPd Rx Pharmaceuticals, Inc.2003-10-23Not applicableUs
Phentermine Hydrochloridetablet30 mg/1oralA S Medication Solutions Llc2013-08-12Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralNorthwind Pharmaceuticals2014-06-01Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralPhysicians Total Care, Inc.2008-01-25Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralProficient Rx LP2003-10-23Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralDispensing Solutions, Inc.2003-10-23Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralLeading Pharma, Llc2015-03-09Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralBlenheim Pharmacal, Inc.2009-12-21Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralRebel Distributors Corp.2003-10-23Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralA S Medication Solutions Llc2012-08-07Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralUnit Dose Services2003-10-23Not applicableUs
Phentermine Hydrochloridetablet30 mg/1oralMutual Pharmaceutical Company, Inc.2013-08-12Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralPd Rx Pharmaceuticals, Inc.2012-08-07Not applicableUs
Phentermine Hydrochloridecapsule37.5 mg/1oralbryant ranch prepack2012-08-15Not applicableUs
Phentermine Hydrochloridecapsule15 mg/1oralPreferred Pharmaceuticals Inc.2015-10-29Not applicableUs
Phentermine Hydrochloridecapsule30 mg/1oralEon Labs, Inc.1981-06-12Not applicableUs
Phentermine Hydrochloridetablet37.5 mg/1oralKvk Tech, Inc.2012-08-15Not applicableUs
Phentermine Resin ERcapsule, extended release15 mg/1oralLannett Company, Inc.2011-07-28Not applicableUs
Phentermine Resin ERcapsule, extended release30 mg/1oralLannett Company, Inc.2011-07-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DuromineNot Available
FastinNot Available
IonaminNot Available
ObenixNot Available
Obestin-30Not Available
PhentercotNot Available
PhentrideNot Available
Pro-FastNot Available
TeramineNot Available
ZantrylNot Available
Brand mixtures
NameLabellerIngredients
QsymiaVIVUS, Inc.
Salts
Name/CASStructureProperties
Phentermine Hydrochloride
1197-21-3
Thumb
  • InChI Key: NCAIGTHBQTXTLR-UHFFFAOYSA-N
  • Monoisotopic Mass: 185.097127224
  • Average Mass: 185.694
DBSALT000138
Categories
UNIIC045TQL4WP
CAS number122-09-8
WeightAverage: 149.2328
Monoisotopic: 149.120449485
Chemical FormulaC10H15N
InChI KeyInChIKey=DHHVAGZRUROJKS-UHFFFAOYSA-N
InChI
InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3
IUPAC Name
2-methyl-1-phenylpropan-2-amine
SMILES
CC(C)(N)CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Aralkylamine
  • Hydrocarbon derivative
  • Primary amine
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment and management of obesity.
PharmacodynamicsPhentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
Mechanism of actionPhentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse.Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.
Related Articles
AbsorptionPhentermine is rapidly absorbed after oral ingestion.
Volume of distributionNot Available
Protein bindingApproximately 96.3%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life16 to 31 hours
ClearanceNot Available
ToxicityLD50 is adult monkeys is 15 to 20 mg/kg. Symptoms of overdose include delirium, mania, self-injury, marked hypertension, tachycardia, arrhythmia, hyperpyrexia, convulsion, coma, and circulatory collapse.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.959
Caco-2 permeable+0.7688
P-glycoprotein substrateNon-substrate0.6477
P-glycoprotein inhibitor INon-inhibitor0.934
P-glycoprotein inhibitor IINon-inhibitor0.9801
Renal organic cation transporterNon-inhibitor0.8236
CYP450 2C9 substrateNon-substrate0.8411
CYP450 2D6 substrateSubstrate0.7204
CYP450 3A4 substrateNon-substrate0.6493
CYP450 1A2 substrateNon-inhibitor0.7962
CYP450 2C9 inhibitorNon-inhibitor0.8861
CYP450 2D6 inhibitorInhibitor0.7825
CYP450 2C19 inhibitorNon-inhibitor0.8996
CYP450 3A4 inhibitorNon-inhibitor0.7348
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8782
Ames testNon AMES toxic0.9681
CarcinogenicityNon-carcinogens0.6949
BiodegradationNot ready biodegradable0.9303
Rat acute toxicity2.8400 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9867
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Baxter healthcare corp anesthesia critical care
  • Teva pharmaceuticals usa inc
  • Glaxosmithkline
  • Ferndale laboratories inc
  • Shire richwood inc
  • Mm mast and co
  • Abc holding corp
  • Able laboratories inc
  • Actavis totowa llc
  • Barr laboratories inc
  • Camall co inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc
  • Kvk tech inc
  • Lannett co inc
  • Lannett holdings inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Tg united inc
  • Tg united labs llc
  • Usl pharma inc
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • Actavis elizabeth llc
  • Caraco pharmaceutical laboratories ltd
  • Vintage pharmaceuticals inc
  • Solvay pharmaceuticals
  • Ucb inc
  • Quantum pharmics ltd
Packagers
Dosage forms
FormRouteStrength
Capsuleoral30 mg
Capsuleoral15 mg/1
Capsuleoral30 mg/1
Capsuleoral37.5 mg/1
Tabletoral30 mg/1
Tabletoral37.5 mg/1
Capsule, extended releaseoral15 mg/1
Capsule, extended releaseoral30 mg/1
Capsule, extended releaseoral
Tablet, orally disintegratingoral15 mg/1
Tablet, orally disintegratingoral30 mg/1
Tablet, orally disintegratingoral37.5 mg/1
Prices
Unit descriptionCostUnit
Phentermine hcl powder10.71USD g
Ionamin 30 mg capsule sa2.87USD capsule
Adipex-P 37.5 mg capsule2.2USD capsule
Adipex-p 37.5 mg tablet2.15USD tablet
Phentermine 37.5 mg tablet1.54USD tablet
Phentermine HCl 15 mg capsule1.18USD capsule
Phentermine HCl 30 mg capsule1.17USD capsule
Ionamin 15 mg capsule sa1.15USD capsule
Phentermine HCl 37.5 mg capsule1.0USD capsule
Phentermine HCl 37.5 mg tablet1.0USD tablet
Phentermine 8 mg tablet0.54USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6071537 No1997-06-232017-06-23Us
US6149938 No1998-07-232018-07-23Us
US7056890 No2000-06-142020-06-14Us
US7553818 No2000-06-142020-06-14Us
US7659256 No2000-06-142020-06-14Us
US7674776 No2000-06-142020-06-14Us
US8440170 No2009-03-142029-03-14Us
US8580298 No2009-05-152029-05-15Us
US8580299 No2009-06-142029-06-14Us
US8895057 No2008-06-092028-06-09Us
US8895058 No2008-06-092028-06-09Us
US9011905 No2008-06-092028-06-09Us
US9011906 No2008-06-092028-06-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point205 °CNot Available
water solubility18.6 g/LNot Available
logP1.90HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.757 mg/mLALOGPS
logP2.32ALOGPS
logP2.08ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)10.25ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity48.34 m3·mol-1ChemAxon
Polarizability17.87 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.33 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0ue9-0900000000-f2eb273dfd0ec45869c5View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0f89-2900000000-f527ee48b9e2784c178cView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0159-4900000000-548f73a83354267c9f81View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0002-0900000000-c7ab0aa268d14ae3da39View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0002-1900000000-ce1c08c021fbc1cc5c8cView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-001i-2900000000-94b2b38953d359938c0aView in MoNA
MSMass Spectrum (Electron Ionization)splash10-0a4i-9100000000-7037d3f1fad22de72c33View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis ReferenceNot Available
General References
  1. Bray GA: A concise review on the therapeutics of obesity. Nutrition. 2000 Oct;16(10):953-60. [PubMed:11054601 ]
  2. Nelson DL, Gehlert DR: Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2006 Feb;29(1):49-60. [PubMed:16622292 ]
External Links
ATC CodesA08AA01
AHFS Codes
  • 28:20.92
PDB EntriesNot Available
FDA labelDownload (159 KB)
MSDSDownload (48.2 KB)
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Phentermine.
AcepromazineAcepromazine may decrease the stimulatory activities of Phentermine.
AcetaminophenThe risk or severity of adverse effects can be increased when Phentermine is combined with Acetaminophen.
AcetazolamideAcetazolamide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
AcetophenazineAcetophenazine may decrease the stimulatory activities of Phentermine.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Phentermine is combined with Acetylsalicylic acid.
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
AminophyllineThe risk or severity of adverse effects can be increased when Phentermine is combined with Aminophylline.
AmisulprideAmisulpride may decrease the stimulatory activities of Phentermine.
AmitriptylineAmitriptyline may increase the stimulatory activities of Phentermine.
Ammonium chlorideThe serum concentration of Phentermine can be decreased when it is combined with Ammonium chloride.
AmphetamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Amphetamine.
ArformoterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Arformoterol.
AripiprazoleAripiprazole may decrease the stimulatory activities of Phentermine.
ArmodafinilThe risk or severity of adverse effects can be increased when Phentermine is combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Phentermine is combined with Articaine.
AtomoxetineAtomoxetine may increase the hypertensive activities of Phentermine.
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Phentermine.
BenzquinamideBenzquinamide may decrease the stimulatory activities of Phentermine.
BrompheniraminePhentermine may decrease the sedative activities of Brompheniramine.
ButalbitalThe risk or severity of adverse effects can be increased when Phentermine is combined with Butalbital.
CaffeineThe risk or severity of adverse effects can be increased when Phentermine is combined with Caffeine.
Calcium AcetateCalcium Acetate may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
Calcium carbonateCalcium carbonate may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
CarphenazineCarphenazine may decrease the stimulatory activities of Phentermine.
ChlormezanoneChlormezanone may decrease the stimulatory activities of Phentermine.
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Phentermine.
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Phentermine.
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Phentermine.
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Phentermine.
ClozapineClozapine may decrease the stimulatory activities of Phentermine.
CocaineThe risk or severity of adverse effects can be increased when Phentermine is combined with Cocaine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Phentermine is combined with Dexmethylphenidate.
DextroamphetamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Dextroamphetamine.
DiclofenamideDiclofenamide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
DiethylpropionThe risk or severity of adverse effects can be increased when Phentermine is combined with Diethylpropion.
DihydrocodeineThe risk or severity of adverse effects can be increased when Phentermine is combined with Dihydrocodeine.
DipivefrinThe risk or severity of adverse effects can be increased when Phentermine is combined with Dipivefrin.
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Phentermine.
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Phentermine.
DoxapramThe risk or severity of adverse effects can be increased when Phentermine is combined with Doxapram.
DoxofyllineThe risk or severity of adverse effects can be increased when Phentermine is combined with Doxofylline.
DronabinolDronabinol may increase the tachycardic activities of Phentermine.
DroperidolDroperidol may decrease the stimulatory activities of Phentermine.
DyphyllineThe risk or severity of adverse effects can be increased when Phentermine is combined with Dyphylline.
EphedrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Ephedrine.
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Phentermine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Phentermine.
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Phentermine.
EthoxzolamideEthoxzolamide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
FencamfamineFencamfamine may decrease the stimulatory activities of Phentermine.
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Phentermine.
FlupentixolFlupentixol may decrease the stimulatory activities of Phentermine.
FluphenazineFluphenazine may decrease the stimulatory activities of Phentermine.
FluspirileneFluspirilene may decrease the stimulatory activities of Phentermine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Phentermine is combined with Fluticasone Propionate.
FormoterolThe risk or severity of adverse effects can be increased when Formoterol is combined with Phentermine.
HaloperidolHaloperidol may decrease the stimulatory activities of Phentermine.
HexamethylenetetramineThe serum concentration of Phentermine can be decreased when it is combined with Hexamethylenetetramine.
IndacaterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Indacaterol.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Phentermine.
Ioflupane I 123Phentermine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Phentermine is combined with Ipratropium bromide.
IsomethepteneThe risk or severity of adverse effects can be increased when Phentermine is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Phentermine.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Phentermine.
LevonordefrinThe risk or severity of adverse effects can be increased when Phentermine is combined with Levonordefrin.
LinezolidLinezolid may increase the hypertensive activities of Phentermine.
LisdexamfetamineThe risk or severity of adverse effects can be increased when Phentermine is combined with Lisdexamfetamine.
LithiumLithium may decrease the stimulatory activities of Phentermine.
LoxapineLoxapine may decrease the stimulatory activities of Phentermine.
Magnesium oxideMagnesium oxide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Phentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Phentermine is combined with Mepivacaine.
MesoridazineMesoridazine may decrease the stimulatory activities of Phentermine.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Phentermine.
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Phentermine.
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Phentermine.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Phentermine.
MethylphenidateThe risk or severity of adverse effects can be increased when Phentermine is combined with Methylphenidate.
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Phentermine.
ModafinilThe risk or severity of adverse effects can be increased when Phentermine is combined with Modafinil.
MolindoneMolindone may decrease the stimulatory activities of Phentermine.
MorphinePhentermine may increase the analgesic activities of Morphine.
NabiloneNabilone may increase the tachycardic activities of Phentermine.
NaphazolineThe risk or severity of adverse effects can be increased when Naphazoline is combined with Phentermine.
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Phentermine.
OlanzapineOlanzapine may decrease the stimulatory activities of Phentermine.
OlodaterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Olodaterol.
OndansetronOndansetron may decrease the stimulatory activities of Phentermine.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Phentermine.
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Phentermine.
PaliperidonePaliperidone may decrease the stimulatory activities of Phentermine.
PerphenazinePerphenazine may decrease the stimulatory activities of Phentermine.
PhendimetrazineThe risk or severity of adverse effects can be increased when Phentermine is combined with Phendimetrazine.
PhenelzinePhenelzine may increase the hypertensive activities of Phentermine.
PheniramineThe risk or severity of adverse effects can be increased when Phentermine is combined with Pheniramine.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Phentermine.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Phentermine.
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Phentermine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Phentermine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Phentermine.
PimozidePimozide may decrease the stimulatory activities of Phentermine.
PiperacetazinePiperacetazine may decrease the stimulatory activities of Phentermine.
PirbuterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Pirbuterol.
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Phentermine.
PromazinePromazine may decrease the stimulatory activities of Phentermine.
PropylhexedrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Propylhexedrine.
PseudoephedrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Pseudoephedrine.
QuetiapineQuetiapine may decrease the stimulatory activities of Phentermine.
RacepinephrineThe risk or severity of adverse effects can be increased when Phentermine is combined with Racepinephrine.
RemoxiprideRemoxipride may decrease the stimulatory activities of Phentermine.
ReserpineReserpine may decrease the stimulatory activities of Phentermine.
RisperidoneRisperidone may decrease the stimulatory activities of Phentermine.
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Phentermine.
SalbutamolThe risk or severity of adverse effects can be increased when Phentermine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Phentermine.
SertindoleSertindole may decrease the stimulatory activities of Phentermine.
SulpirideSulpiride may decrease the stimulatory activities of Phentermine.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Phentermine.
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Phentermine.
TheophyllineThe risk or severity of adverse effects can be increased when Phentermine is combined with Theophylline.
ThioridazineThioridazine may decrease the stimulatory activities of Phentermine.
ThiothixeneThiothixene may decrease the stimulatory activities of Phentermine.
TranylcypromineTranylcypromine may increase the hypertensive activities of Phentermine.
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Phentermine.
TriflupromazineTriflupromazine may decrease the stimulatory activities of Phentermine.
TriprolidineThe risk or severity of adverse effects can be increased when Phentermine is combined with Triprolidine.
VilanterolThe risk or severity of adverse effects can be increased when Phentermine is combined with Vilanterol.
Vitamin CThe serum concentration of Phentermine can be decreased when it is combined with Vitamin C.
ZiprasidoneZiprasidone may decrease the stimulatory activities of Phentermine.
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Phentermine.
Food Interactions
  • Limit caffeine intake.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Stephens LC, Katz SG: Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7. [PubMed:16119498 ]
  4. Samanin R, Garattini S: Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol. 1993 Aug;73(2):63-8. [PubMed:7902561 ]
  5. Proietto J, Fam BC, Ainslie DA, Thorburn AW: Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. [PubMed:11060745 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. John CE, Jones SR: Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology. 2007 Jun;52(8):1596-605. Epub 2007 Mar 16. [PubMed:17459426 ]
  2. Johnson GJ, Leis LA, Dunlop PC, Weir EK: The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux. J Thromb Haemost. 2003 Dec;1(12):2663-8. [PubMed:14675103 ]
  3. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, Seif I, Benhaiem-Sigaux N, Kirsch M, Hamon M, Adnot S, Eddahibi S: Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation. 2006 Jan 3;113(1):81-9. Epub 2005 Dec 27. [PubMed:16380550 ]
  4. Rothman RB, Ayestas MA, Dersch CM, Baumann MH: Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation. 1999 Aug 24;100(8):869-75. [PubMed:10458725 ]
  5. Zolkowska D, Rothman RB, Baumann MH: Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006 Aug;318(2):604-10. Epub 2006 Apr 27. [PubMed:16644904 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. John CE, Jones SR: Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology. 2007 Jun;52(8):1596-605. Epub 2007 Mar 16. [PubMed:17459426 ]
  2. Gruner JA, Marcy VR, Lin YG, Bozyczko-Coyne D, Marino MJ, Gasior M: The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. Sleep. 2009 Nov;32(11):1425-38. [PubMed:19928382 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Rothman RB: Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. Synapse. 1999 May;32(2):141-5. [PubMed:10231134 ]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660 ]
  3. Kilpatrick IC, Traut M, Heal DJ: Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1454-8. [PubMed:11673765 ]
  4. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Rothman RB: Does phentermine inhibit monoamine oxidase? Lancet. 1999 Apr 17;353(9161):1362-3. [PubMed:10218558 ]
  2. Rothman RB: Is phentermine an inhibitor of monoamine oxidase? A critical appraisal. Synapse. 1999 May;32(2):141-5. [PubMed:10231134 ]
  3. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660 ]
  4. Kilpatrick IC, Traut M, Heal DJ: Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1454-8. [PubMed:11673765 ]
  5. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838 ]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B. Biochem Pharmacol. 2002 Mar 1;63(5):865-9. [PubMed:11911838 ]
  2. Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21. [PubMed:10799660 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 28, 2016 01:52